The IPA has been informed that Spark Therapeutics has realigned its portfolio and made the difficult decision to stop its Pompe program. This includes the Phase 1/2 Investigational Gene Transfer Study, Resolute, for Adults with Late-Onset Pompe Disease (LOPD). Spark Therapeutics Stops Its Pompe Program - International Pompe Association (worldpompe.org)   APPROVED-FINAL-Pompe-Community-Letter